UConn, CaroGen collaborate re colorectal treatment

Researchers at UConn Health and CaroGen, a biopharmaceutical company based at UConn’s Technology Incubation Program (TIP) facility in Farmington, have developed a promising clinical candidate for colorectal cancer treatment.

Kepeng Wang, assistant professor of immunology at UConn Health and a member of CaroGen’s Scientific Advisory Board, identified CARG-2020 as an oncolytic vector – a virus that infects and kills cancer cells – with the capacity to impact three critical cancer pathways.